Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVt vaccine in infants and toddlers
NCT05687279Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of RSVt vaccine in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of Placebo Receiving Pediatric Participants With Vaccine Virus Detected in Nasal Swabs After the First Vaccination at Day 22, Titer of Vaccine Virus Shedding in All Pediatric Participants Detected in Nasal Swabs at Day 71 and 1 more. Started Feb 2023; status: completed.
02
Drugs
RSVt vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05687279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687279.